Tecan's Capital Markets Day: Strategic Growth and Groundbreaking Innovation
Tuesday, Oct 22, 2024 1:25 am ET
1min read Tecan Group, a leading provider of laboratory instruments and solutions, hosted its Capital Markets Day on October 22, 2024, in Männedorf, Switzerland. The event showcased the company's strategic growth drivers, groundbreaking innovation, and product launches, reaffirming its mid-term financial outlook and commitment to outperform the average growth rate of its underlying end markets.
Tecan is targeting high-growth applications in genomics, cell and tissue, and proteomics markets. Its products aim to unlock bottlenecks in key workflows, accelerating reliable, scalable processes and delivering reproducible results. Additionally, Tecan's Partnering Business is addressing fast-growing segments in medtech, such as soft tissue and orthopedic robotic surgery, as well as products for cardiovascular applications.
The company's rapid innovation is driven by the modularity of its powerful software and hardware platforms, which serve both its Life Sciences Business and Partnering Business divisions. Tecan demonstrated its groundbreaking new multiomics platform at the event, which redefines lab automation by leveraging shared hardware and software platforms. This modular approach enables fast-paced innovation and accelerates the development of new systems.
Tecan has established a leading open digital ecosystem for laboratories, with user-friendly interfaces for operators, managers, and systems. Its digital building blocks accelerate the development of robust, tailored solutions for high-performance applications, facilitating even the cutting edge of AI-driven analytics and drug discovery.
Strategic partnerships play a crucial role in Tecan's growth strategy. The company is uniquely positioned to partner with life science, lab diagnostics, and medtech companies to accelerate market adoption of their innovative healthcare solutions. At the Capital Markets Day, Tecan provided details about high-value long-term partnerships, including new relationships, which contribute to its financial success and enable it to outperform growth in the underlying end markets.
Tecan's CFO, Tania Micki, presented a selection of the company's programs and drivers for further EBITDA expansion. These include leveraging economies of scale, vertical integration, modularity in R&D, and process improvements, leading to an average annual increase in the adjusted EBITDA margin of +30-50 basis points, based on the original 2024 outlook of around 20%.
Tecan's demonstrated track record of above-market growth, margin expansion, strong cash conversion, and CAPEX-light requirements have created a healthy basis for continued pursuit of an accretive M&A strategy. Supported by a range of strategic growth drivers, Tecan anticipates returning to average organic growth rates in the mid to high single-digit percentage range in local currencies under normal market conditions.
The Capital Markets Day webcast can be accessed at.
Tecan is targeting high-growth applications in genomics, cell and tissue, and proteomics markets. Its products aim to unlock bottlenecks in key workflows, accelerating reliable, scalable processes and delivering reproducible results. Additionally, Tecan's Partnering Business is addressing fast-growing segments in medtech, such as soft tissue and orthopedic robotic surgery, as well as products for cardiovascular applications.
The company's rapid innovation is driven by the modularity of its powerful software and hardware platforms, which serve both its Life Sciences Business and Partnering Business divisions. Tecan demonstrated its groundbreaking new multiomics platform at the event, which redefines lab automation by leveraging shared hardware and software platforms. This modular approach enables fast-paced innovation and accelerates the development of new systems.
Tecan has established a leading open digital ecosystem for laboratories, with user-friendly interfaces for operators, managers, and systems. Its digital building blocks accelerate the development of robust, tailored solutions for high-performance applications, facilitating even the cutting edge of AI-driven analytics and drug discovery.
Strategic partnerships play a crucial role in Tecan's growth strategy. The company is uniquely positioned to partner with life science, lab diagnostics, and medtech companies to accelerate market adoption of their innovative healthcare solutions. At the Capital Markets Day, Tecan provided details about high-value long-term partnerships, including new relationships, which contribute to its financial success and enable it to outperform growth in the underlying end markets.
Tecan's CFO, Tania Micki, presented a selection of the company's programs and drivers for further EBITDA expansion. These include leveraging economies of scale, vertical integration, modularity in R&D, and process improvements, leading to an average annual increase in the adjusted EBITDA margin of +30-50 basis points, based on the original 2024 outlook of around 20%.
Tecan's demonstrated track record of above-market growth, margin expansion, strong cash conversion, and CAPEX-light requirements have created a healthy basis for continued pursuit of an accretive M&A strategy. Supported by a range of strategic growth drivers, Tecan anticipates returning to average organic growth rates in the mid to high single-digit percentage range in local currencies under normal market conditions.
The Capital Markets Day webcast can be accessed at
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
